US House panel advances legislation restricting business with Chinese biotech firms
WASHINGTON, May 15 (Reuters) - A U.S. House committee on Wednesday voted to advance legislation that would restrict business with China's BGI, WuXi AppTec 603259.SS and certain other biotech companies on national security grounds. (Reporting by Karen Freifeld and Makini Brice) ((M.Brice@thomsonreuters.com;))
Recent news on WuXi Biologics (Cayman)
See all newsHong Kong stocks end higher on pharma, tech gains
Hong Kong stocks climb, led by pharmaceutical, tech stocks
CanSino leads HK-listed vaccine makers lower as BioNTech halts mRNA trial
WuXi Biologics H1 net profit up on margin expansion
Brief: WuXi Biologics Logs HY Net Profit Attributable RMB 2,439.8 Mln